Brian  Piper net worth and biography

Brian Piper Biography and Net Worth

Brian Piper, M.B.A currently serves as Chief Financial Officer at Prelude Therapeutics. Mr. Piper joined Prelude in 2019 and has over 25 years of experience in corporate healthcare finance, covering a wide span of financial and operational activities. Prior to joining Prelude, Mr. Piper served as Chief Financial Officer and Corporate Secretary at Aevi Genomic Medicine (later acquired by Cerecor, Inc.). Prior to his time with Aevi, Mr. Piper served as Vice President, Finance and Investor Relations at Medgenics, Inc. from 2014 to 2016, and prior to Medgenics, had a 13- year career at Shire Pharmaceuticals (later acquired by Takeda Pharmaceutical Company Limited), holding key roles in Investor Relations, Corporate Venture Capital, and numerous additional financial roles, including two years spent in Dublin, Ireland establishing Shire’s geographic expansion strategies. Early in his career, Mr. Piper also spent time with Celera Genomics and Otsuka Pharmaceuticals, Inc. Mr. Piper received his B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.

What is Brian Piper's net worth?

The estimated net worth of Brian Piper is at least $39,498.42 as of August 25th, 2021. Mr. Piper owns 8,333 shares of Prelude Therapeutics stock worth more than $39,498 as of March 29th. This net worth estimate does not reflect any other assets that Mr. Piper may own. Learn More about Brian Piper's net worth.

How do I contact Brian Piper?

The corporate mailing address for Mr. Piper and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on Brian Piper's contact information.

Has Brian Piper been buying or selling shares of Prelude Therapeutics?

Brian Piper has not been actively trading shares of Prelude Therapeutics during the last quarter. Most recently, Brian Piper sold 8,333 shares of the business's stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $33.34, for a transaction totalling $277,822.22. Following the completion of the sale, the chief financial officer now directly owns 8,333 shares of the company's stock, valued at $277,822.22. Learn More on Brian Piper's trading history.

Who are Prelude Therapeutics' active insiders?

Prelude Therapeutics' insider roster includes Andrew Combs (EVP), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.

Are insiders buying or selling shares of Prelude Therapeutics?

In the last year, Prelude Therapeutics insiders bought shares 2 times. They purchased a total of 870,565 shares worth more than $5,005,008.75. In the last year, insiders at the sold shares 1 times. They sold a total of 13,280 shares worth more than $81,273.60. The most recent insider tranaction occured on May, 24th when CEO Krishna Vaddi bought 1,000 shares worth more than $5,010.00. Insiders at Prelude Therapeutics own 79.5% of the company. Learn More about insider trades at Prelude Therapeutics.

Information on this page was last updated on 5/24/2023.

Brian Piper Insider Trading History at Prelude Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2021Sell8,333$33.34$277,822.228,333View SEC Filing Icon  
5/25/2021Sell8,333$34.27$285,571.918,333View SEC Filing Icon  
See Full Table

Brian Piper Buying and Selling Activity at Prelude Therapeutics

This chart shows Brian Piper's buying and selling at Prelude Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Prelude Therapeutics Company Overview

Prelude Therapeutics logo
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $4.74
Low: $4.72
High: $5.00

50 Day Range

MA: $3.93
Low: $2.68
High: $4.84

2 Week Range

Now: $4.74
Low: $1.66
High: $8.56

Volume

32,074 shs

Average Volume

49,063 shs

Market Capitalization

$260.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49